Biological E

According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin.

Biological E gets DCGI nod to market Pneumococcal Conjugate Vaccine in India

The company said 14-valent paediatric Pneumococcal Conjugate Vaccine (PCV14) against S. pneumoniae infection may be administered to infants 6, 10 and 14 weeks of age in three doses.

Biological-E developing Omicron specific vaccine, contemplating it to be used as bivalent jab: Mahima Datla, CEO

The managing director of vaccine manufacturing company says regulatory framework along with financing and market predictability are important bottlenecks in developing variant specific vaccines against evolving coronavirus

SEC recommends Biological E's vaccine against S pneumonia for infants

Streptococcus pneumoniae infection continues to be a leading cause of child mortality under 5 years of age in India and in developing countries

31 companies express interest in developing Monkeypox vaccines, kits; Serum, Biological E in race

The official said that the Serum Institute of India, Biological E, and Indian Immunological have expressed their interest in developing a vaccine for Monkeypox.

From August 12, option of Corbevax as booster doses for all jabbed with Covaxin, Covishield earlier

The recipients of Covaxin and Covishield, however, will also have an option of receiving the same vaccine they had taken for their primary vaccination

Centre plans second-generation COVID vaccines to tackle mutating variants 

But immunologists are not convinced, noting that new vaccines may not be needed as COVID has become endemic. 

Corbevax as booster dose after Covaxin, Covishield? Top panel on immunisation to discuss possibility

Last year, the Union government had paid an advance of Rs 1,500 crore to Corbevax maker Biological E to procure 30 crore doses of the vaccine, which was still in phase 3 clinical trials, in the first such deal to secure a vaccine.

Top virologists weigh in for Corbevax booster after primary vaccination with Covishield, Covaxin 

The pharma regulator has approved the first mix-and-match of COVID-19 vaccines in India, but the final say-so lies with the government 

Biological E. cuts price of its COVID-19 vaccine to Rs 250 per dose

Previously, in private vaccination centres the overall cost to end users of the vaccine was Rs 990 a dose, including taxes and administration charges, it added.

Exclusive: Supplied nearly 100 million doses to Govt; committed to meeting growing demand for Corbevax: Biological E’s COO

Data on the Omicron variant in children was not part of our clinical trial endpoints. We have submitted all the data generated against multiple variants to regulatory agencies including NTAGI. We are regularly making presentations to the regulatory bodies as more and more data gets generated, says Lakshminarayana Neti

COVID-19 vaccines for 5-11-year-olds may be limited to private hospitals 

Government approval for the administration of COVID-19 vaccines to children in the 5-11-year age group is possible as early as next week, according to health ministry officials familiar with the situation. 

Biological E to get mRNA technology from WHO to produce COVID-19 vaccines

A press release from BE Limited said the WHO's Advisory Committee on Vaccine Product Development (ACPDV) selected the firm after examining a number of proposals from India, as a recipient of mRNA (ribonucleic acid) technology from the global health body's technology transfer hub.

Huge response to COVID-19 shots for 12-14 age group; private hospitals keep away

Private healthcare providers struggling to use up their stocks of Covishield and Covaxin shots are showing no enthusiasm for the Corbevax vaccination of children.

COVID-19 Vaccine | Govt to procure Corbevax at Rs 290 for two doses, private hospitals at Rs 800

On March 16, India began the inoculation drive for children aged 12 to 14 years, administering only the Corbevax COVID-19 vaccine to the beneficiaries.

In Depth | As demand for COVID-19 vaccine dips in India, government and companies look to step up exports

Average daily COVID-19 vaccinations in February dipped to 2-2.2 million from a high of nearly 8 million in August. The fall, coupled with a decline in the number of coronavirus disease cases, is prompting the Centre to give a push to vaccine exports.

COVID-19 Vaccine | Corbevax gets DCGI nod for emergency use in 12-18 year olds

The development comes even as the government is yet to decide on the expansion of the ongoing national immunisation campaign against coronavirus for kids and adolescents under 15 years.

Biological E seeks EUA for its Corbevax vaccine for 12-18 yrs age group

The Drugs Controller General Of India (DCGI) has already approved Corbevax, which is India's first indigenously developed RBD protein sub-unit vaccine against COVID-19, for restricted use in emergency situation among adults on December 28.

COVID-19 Vaccine | India to get first supply of Corbevax from February 15: Report

Sources said the Central Drugs Laboratory in Kasauli has already approved 65 million doses of Corbevax for use through government vaccination centres.

Centre places purchase order for 5 crore doses of Corbevax Covid vaccine each costing Rs 145 sans tax

The government is yet to decide on which segment of beneficiaries this new vaccine would be administered.

About 1 crore doses of SII's Covovax cleared by govt lab for public use, testing of Bio E's Corbevax to begin

While the decision on mix and match remains pending, the Modi government seems to be in a comfortable position on availability of vaccines to kickstart boosters or open precautionary doses for another age group, said an official.

Biological E aims to produce 100 million doses/month of Corbevax from February 2022

Corbevax, India's first indigenously developed protein sub-unit vaccine against the virus, received the approval from the Drugs Controller General of India (DGCI) today, it said.

DFC to finance $50 million to Biological E to expand COVID-19 vaccine manufacturing capacity

The agreement will help bolster near-term COVID-19 response efforts and will also benefit long-term global health in India and throughout the Indo-Pacific region.

Mansukh Mandaviya holds meeting with Biological-E MD on progress of COVID vaccine

The health minister on Thursday had also held a meeting with Dr Reddy's Laboratories Chairman Satish Reddy regarding the production and supply of COVID-19 vaccine Sputnik V.

COVID-19 Vaccines | Biological E to begin producing 75-80 million doses of vaccine candidate from August 2021

The company is also starting Phase III trials of its recombinant protein vaccine candidate from August.